Madhu Kumar
Stock Analyst at Goldman Sachs
(2.83)
# 1,633
Out of 5,141 analysts
142
Total ratings
55.1%
Success rate
19.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $172.19 | +7.44% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $11.00 | -45.45% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $9.70 | +75.26% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.99 | +101.01% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $261.80 | -40.79% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $67.94 | -21.99% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $10.11 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $63.59 | +14.80% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $22.28 | +532.85% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $19.69 | +72.68% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.87 | +109.06% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $7.67 | +82.53% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $29.31 | -82.94% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.79 | +346.93% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $11.99 | +642.29% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $8.61 | +1,293.73% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $12.64 | +572.47% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.90 | +900.00% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $23.43 | +143.28% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.27 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.76 | +118,664.85% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $7.56 | +164.55% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.24 | +42,165.43% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $48.00 | -27.08% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $15.33 | +160.93% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $28.75 | +1,653.04% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $336.19 | -31.59% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $11.60 | +9,598.28% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.89 | +4,370.77% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $29.53 | -27.19% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $53.46 | -56.04% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $172.19
Upside: +7.44%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $11.00
Upside: -45.45%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $9.70
Upside: +75.26%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.99
Upside: +101.01%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $261.80
Upside: -40.79%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $67.94
Upside: -21.99%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $10.11
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $63.59
Upside: +14.80%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $22.28
Upside: +532.85%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $19.69
Upside: +72.68%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.87
Upside: +109.06%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $7.67
Upside: +82.53%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $29.31
Upside: -82.94%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.79
Upside: +346.93%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $11.99
Upside: +642.29%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $8.61
Upside: +1,293.73%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $12.64
Upside: +572.47%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.90
Upside: +900.00%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $23.43
Upside: +143.28%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.27
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.76
Upside: +118,664.85%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $7.56
Upside: +164.55%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.24
Upside: +42,165.43%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $48.00
Upside: -27.08%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $15.33
Upside: +160.93%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $28.75
Upside: +1,653.04%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $336.19
Upside: -31.59%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $11.60
Upside: +9,598.28%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.89
Upside: +4,370.77%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $29.53
Upside: -27.19%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $53.46
Upside: -56.04%